News
Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...
GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...
In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 to a brand-name GLP-1 ...
GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make the process of switching from a compounded GLP-1 ...
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.
What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback